Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The European Medicine Agency's outgoing Executive Director Thomas Lönngren discusses his 10 years on the job, the importance of regulatory science and the challenges that lie ahead for his successor.
As the US FDA prepares to implement an abbreviated pathway for follow-on biologics, it gathered stakeholders to discuss key concerns. Analytical assessment and clinical development programmes were high on the agenda.